RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM

RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00457964

Enrollment

Registered

2007-04-09

Start date

2005-08-31

Completion date

2013-07-31

Last updated

2013-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphangioleiomyomatosis, Tuberous Sclerosis

Keywords

Tuberous Sclerosis Complex (TSC), Lymyphangioleiomyomatosis, Mammalian Target of Rapamycin (mTOR), RAD001, Angiomyolipmas

Brief summary

The purpose of this research study is to find out what effects RAD001 has on angiomyolipomas of a person with Tuberous Sclerosis Complex and to determine the safe dose of RAD001 without toxicity. The hypothesis is that the drug will inhibit the growth of the angiomyolipomas and possibly even cause regression.

Detailed description

Tuberous sclerosis complex is a genetic disorder with a birth incidence of approximately one in six thousand. Angiomyolipomas occur in eighty percent of persons with TS, and in up to 60% of persons with LAM. They are fatty tumors that often occur in kidney or liver as well as other parts of the body. They can grow and cause damage to surrounding kidney tissue and even renal failure. They may also leak blood causing potentially life-threatening hemorrhage. Laboratory studies have shown that RAD001 suppresses the chemical that cause tumors to grow in tuberous sclerosis and sporadic LAM. The primary goal of this study is to evaluate the clinical effectiveness of RAD001 in a 24 month trial. Although the primary goal is to determine if the drug RAD001 has effects on angiomyolipomas, other diseases associated with tuberous sclerosis will be monitored too, specifically any change in involvement of your brain or lungs with tuberous sclerosis. The use of RAD001 to treat angiomyolipomas in tuberous sclerosis or sporadic LAM is considered experimental

Interventions

DRUGRAD001

5 and 10 mg/day or 30, 50, 70mg/week

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosed with angiomyolipomas and have either Tuberous Sclerosis Complex or lymphangioleiomyomatosis * Angiomyolipoma one centimeter or greater in largest diameter * Between the ages of 18 and 65 years old. * If female, documentation of negative pregnancy test prior to enrollment and, where applicable, use of appropriate non-estrogen containing birth control contraceptive regimen while on study. * Adequate renal function (creatinine \< 3 mg/dl)

Exclusion criteria

* Pregnant or lactating women * Continuous requirement for supplemental oxygen * Surgery within past 2 months * Use of an investigational drug within last 30 days.

Design outcomes

Primary

Measure	Time frame
Patients will be considered responders if their angiomyolipoma volume decreases by thirty percent or more from baseline	12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026